Send me a link:

*Text messaging rates may apply.

 Dow Up0.36% Nasdaq Up0.71%

Regulus Therapeutics Inc. (RGLS)

6.88 Up 0.21(3.15%) Jul 22, 3:59PM EDT
ProfileGet Profile for:
Regulus Therapeutics Inc.
3545 John Hopkins Court
Suite 210
San Diego, CA 92121
United States - Map
Phone: 858-202-6300

Index Membership:N/A
Full Time Employees:74

Business Summary 

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Regulus Therapeutics Inc.

Corporate Governance 
Regulus Therapeutics Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 4; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Kleanthis G. Xanthopoulos Ph.D., 56
Chief Exec. Officer, Pres, Principal Financial & Accounting Officer and Director
Dr. Neil W. Gibson Ph.D., 58
Chief Scientific Officer
Amy Conrad ,
Director of Investor Relations & Corp. Communications
Mr. David L. Szekeres , 40
Chief Bus. Officer, Gen. Counsel and Sec.
Dr. Zachary A. Zimmerman Ph.D.,
Director of Bus. Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.